Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis

Everolimus Monotherapy or Combined Therapy in Liver Transplantation: Indications and Results

(2013) C. Alegre et al.   TRANSPLANTATION PROCEEDINGS

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma

(2012) H.-S. Shiah et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation-PROTECT

(2012) L. Fischer et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Everolimus With Reduced Tacrolimus Improves Renal Function inDe NovoLiver Transplant Recipients: A Randomized Controlled Trial

(2012) P. De Simone et al.   AMERICAN JOURNAL OF TRANSPLANTATION

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma

(2012) H. E. Thomas et al.   Science Translational Medicine

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

(2011) Matthew G. Fury et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeted Therapies for Hepatocellular Carcinoma

(2011) Augusto Villanueva et al.   GASTROENTEROLOGY

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

(2011) Chiao-Fang Teng et al.   HEPATOLOGY

Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma

(2011) Kenya Yamanaka et al.   HEPATOLOGY RESEARCH

Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma

(2011) Kenya Yamanaka et al.   JOURNAL OF GASTROENTEROLOGY

Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma

(2011) Hwi Young Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

m-TOR inhibitors: What role in liver transplantation?

(2011) Toshiyasu Kawahara et al.   JOURNAL OF HEPATOLOGY

Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis

(2011) Koji Kitamura et al.   JOURNAL OF HEPATOLOGY

mTOR links oncogenic signaling to tumor cell metabolism

(2011) Jessica L. Yecies et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

(2011) Carlos Gomez-Martin et al.   LIVER TRANSPLANTATION

Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

(2011) Faouzi Saliba et al.   LIVER TRANSPLANTATION

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

(2011) A.-C. Piguet et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

(2010) Terry OʼReilly et al.   ANTI-CANCER DRUGS

Everolimus

(2010) P. J. Houghton   CLINICAL CANCER RESEARCH

Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma

(2010) Diego F. Calvisi et al.   GASTROENTEROLOGY

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Management of Hepatocellular Carcinoma Recurrence After Liver Transplantation

(2010) A. Valdivieso et al.   TRANSPLANTATION PROCEEDINGS

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

(2009) D Cejka et al.   BRITISH JOURNAL OF CANCER

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

An Emerging Role of mTOR in Lipid Biosynthesis

(2009) Mathieu Laplante et al.   CURRENT BIOLOGY

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma

(2009) Christian Toso et al.   HEPATOLOGY

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

(2009) Wen Wee Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non-Small Cell Lung Cancer with the mTOR Inhibitor Everolimus

(2009) L. Nogova et al.   JOURNAL OF NUCLEAR MEDICINE

Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy

(2009) Nao Hosokawa et al.   MOLECULAR BIOLOGY OF THE CELL

Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness

(2008) Adriana Sergio et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression

(2008) Carolyn L. Buller et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

(2008) C Le Tourneau et al.   BRITISH JOURNAL OF CANCER

Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

(2008) Ka Ho Tam et al.   CANCER LETTERS

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

(2008) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel advancements in the management of hepatocellular carcinoma in 2008

(2008) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function

(2008) Paolo De Simone et al.   TRANSPLANT INTERNATIONAL